secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001549595-24-000024
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold
--------------------------------------------------------------------------------

- FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.
- Cash and investments $295.3M as of Nov 30, 2023, up from $268.7M at Aug 31, 2023.
- NX-5948 granted FDA Fast Track for CLL; positive Phase 1 data with durable responses.
- NX-2127 placed on partial clinical hold by FDA; expects to resolve in 2024.
- Generated $100M non-dilutive capital from partners in 2023; licensed IRAK-4 degrader NX-0479/GS-6791 to Gilead.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/0001549595-24-000024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000024/nrix-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer